Published in FEBS Lett on August 15, 2005
Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res (2015) 0.98
Pericytopathy: oxidative stress and impaired cellular longevity in the pancreas and skeletal muscle in metabolic syndrome and type 2 diabetes. Oxid Med Cell Longev (2010) 0.97
Ultrastructure of islet microcirculation, pericytes and the islet exocrine interface in the HIP rat model of diabetes. Exp Biol Med (Maywood) (2008) 0.96
Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. Diabetes (2010) 0.94
Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction. Int J Inflam (2012) 0.89
Lens epithelial cell apoptosis initiates diabetic cataractogenesis in the Zucker diabetic fatty rat. Graefes Arch Clin Exp Ophthalmol (2010) 0.89
Cellular mechanisms of high mobility group 1 (HMGB-1) protein action in the diabetic retinopathy. PLoS One (2014) 0.89
PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies. PPAR Res (2008) 0.86
Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. Diabetol Metab Syndr (2014) 0.84
Accumulation of argpyrimidine, a methylglyoxal-derived advanced glycation end product, increases apoptosis of lens epithelial cells both in vitro and in vivo. Exp Mol Med (2012) 0.84
New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vasc Health Risk Manag (2010) 0.82
Cytoplasmic translocation of high-mobility group box-1 protein is induced by diabetes and high glucose in retinal pericytes. Mol Med Rep (2016) 0.78
Angiotensin II-related hypertension and eye diseases. World J Cardiol (2014) 0.78
Litsea japonica extract inhibits neuronal apoptosis and the accumulation of advanced glycation end products in the diabetic mouse retina. Mol Med Rep (2015) 0.78
Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes. Mol Med (2015) 0.77
Extract of Adenanthera pavonina L. seed reduces development of diabetic nephropathy in streptozotocin-induced diabetic rats. Avicenna J Phytomed (2012) 0.76
Involvement of TAGE-RAGE System in the Pathogenesis of Diabetic Retinopathy. J Ophthalmol (2010) 0.76
The Extract of Aster Koraiensis Prevents Retinal Pericyte Apoptosis in Diabetic Rats and Its Active Compound, Chlorogenic Acid Inhibits AGE Formation and AGE/RAGE Interaction. Nutrients (2016) 0.75
Ascorbic acid repletion: A possible therapy for diabetic macular edema? Free Radic Biol Med (2016) 0.75
Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet (2002) 7.11
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol (2006) 3.43
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J (2003) 3.29
Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation (2002) 3.20
Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension (2004) 2.89
Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens (2008) 2.54
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (2010) 2.37
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol (2010) 2.36
Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol (2002) 2.26
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des (2005) 2.06
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging (2011) 2.00
Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol (2007) 1.98
Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.86
Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes. J Mol Cell Cardiol (2002) 1.86
Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol (2007) 1.85
Apoptosis induced by inhibition of cyclic AMP response element-binding protein in vascular smooth muscle cells. Circulation (2003) 1.81
Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest (2003) 1.79
Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med (2007) 1.79
Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells (2008) 1.72
Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res (2006) 1.70
Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun (2002) 1.70
Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J (2008) 1.70
Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ Res (2007) 1.70
Mechanisms for atrial fibrillation in patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2002) 1.67
Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev (2010) 1.66
Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol (2013) 1.66
Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int (2012) 1.62
Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation (2004) 1.61
Ultrasound stimulation restores impaired neovascularization-related capacities of human circulating angiogenic cells. Cardiovasc Res (2012) 1.57
Roles of endogenous monocyte chemoattractant protein-1 in ischemia-induced neovascularization. J Am Coll Cardiol (2004) 1.56
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens (2014) 1.56
Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circ J (2007) 1.55
Prediction of coronary artery disease in patients undergoing carotid endarterectomy. J Neurosurg (2005) 1.55
Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol (2007) 1.54
Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol (2007) 1.53
How to avoid development of AV block during RF ablation: anatomical and electrophysiological analyses at the time of AV node ablation. Pacing Clin Electrophysiol (2012) 1.45
Large blood pressure variability aggravates arteriolosclerosis and cortical sclerotic changes in the kidney in hypertensive rats. Circ J (2014) 1.45
Comparison of gene expression profiling in pressure and volume overload-induced myocardial hypertrophies in rats. Hypertens Res (2006) 1.45
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension--a prospective, randomized, open-labeled, parallel-group, multicenter trial. Hypertens Res (2012) 1.43
RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular weight heparin. Diabetes (2006) 1.43
Low DBP may not be an independent risk for cardiovascular death in revascularized coronary artery disease patients. J Hypertens (2011) 1.42
Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun (2004) 1.39
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun (2002) 1.36
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J (2002) 1.32
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol (2013) 1.31
Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem (2006) 1.30
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol (2004) 1.29
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem (2002) 1.27
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism (2006) 1.26
Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J Diabetes Complications (2002) 1.26
Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. J Clin Invest (2002) 1.25
Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) (2010) 1.24
Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging (2010) 1.24
Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. Biochim Biophys Acta (2011) 1.23
Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer (2009) 1.22
Hypoxic preconditioning augments efficacy of human endothelial progenitor cells for therapeutic neovascularization. Lab Invest (2003) 1.22
Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes (2006) 1.22
Serum C-reactive protein levels predict survival in hepatocellular carcinoma. Liver Int (2007) 1.21
Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev (2007) 1.21
Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun (2009) 1.19
Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol (2006) 1.19
Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res (2005) 1.19
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int (2004) 1.19
Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci (2005) 1.19
Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun (2002) 1.19
A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Res (2007) 1.18
Characterization of glycoconjugate antigens in mouse embryonic neural precursor cells. J Neurochem (2005) 1.17
Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med (2007) 1.14
Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract (2006) 1.13
Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol (2004) 1.12
TAGE (toxic AGEs) theory in diabetic complications. Curr Mol Med (2006) 1.10
A novel secreted protease from Pseudomonas aeruginosa activates NF-kappaB through protease-activated receptors. Cell Microbiol (2008) 1.10
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res (2011) 1.10
Very long chain N-3 fatty acids intake and carotid atherosclerosis: an epidemiological study evaluated by ultrasonography. Atherosclerosis (2004) 1.10
Roles of lipid rafts in integrin-dependent adhesion and gp130 signalling pathway in mouse embryonic neural precursor cells. Genes Cells (2004) 1.10
Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs (2008) 1.10